信達生物(01801.HK)擬根據一般授權配售5200萬股 總籌約47.3億港元
格隆匯 1 月 15日丨信達生物(01801.HK)發佈公吿,2021年1月15日(交易時段前),公司與聯席配售代理訂立配售協議,據此,公司同意委任聯席配售代理作為配售代理行事,以作為公司的代理根據配售協議所載的條款並在其條件規限下,促使承配人(否則自行)以配售價購買5200萬股配售股份。
配售股份相當於於本公吿日期已發行股份總數的約3.70%;及完成配售事項後經擴大已發行股份總數的約3.57%。配售事項所得款項總額預期約為47.268億港元,而所得款項淨額將約為46.706億港元。按此計算,每股配售股份的淨價將約為89.82港元。
公吿表示,配售事項所得款項淨額將用作加快投資及開發公司全球領先創新產品的多項臨牀試驗計劃;撥付潛在產品授權及可能進行併購活動的資金;進一步擴大產能;及營運資金及其他一般企業用途。公司將向聯交所申請批准配售股份上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.